PPARG as therapeutic target for antifibrotic therapy.
作者信息
Ghallab Ahmed, Seddek Abdellatief
机构信息
Department of Forensic Medicine and Toxicology, Faculty of Veterinary Medicine, South Valley University, Qena 83523, Egypt.
出版信息
EXCLI J. 2020 Feb 28;19:227-229. doi: 10.17179/excli2020-1136. eCollection 2020.
Abstract
摘要
相似文献
1
PPARG as therapeutic target for antifibrotic therapy.过氧化物酶体增殖物激活受体γ（PPARG）作为抗纤维化治疗的靶点。
EXCLI J. 2020 Feb 28;19:227-229. doi: 10.17179/excli2020-1136. eCollection 2020.
2
Genomic Activation of Reveals a Candidate Therapeutic Axis in Bladder Cancer.[基因名称]的基因组激活揭示了膀胱癌中的一个候选治疗轴。 （你原文中“of ”后面缺少具体内容，请补充完整以便准确翻译）
Cancer Res. 2017 Dec 15;77(24):6987-6998. doi: 10.1158/0008-5472.CAN-17-1701. Epub 2017 Sep 18.
3
PPARG Drives Molecular Networks as an Inhibitor for the Pathologic Development and Progression of Lung Adenocarcinoma.PPARG作为肺腺癌病理发展和进展的抑制剂驱动分子网络。
PPAR Res. 2020 Apr 26;2020:6287468. doi: 10.1155/2020/6287468. eCollection 2020.
4
MicroRNA-27b-3p Promotes Tumor Progression and Metastasis by Inhibiting Peroxisome Proliferator-Activated Receptor Gamma in Triple-Negative Breast Cancer.微小RNA-27b-3p通过抑制三阴性乳腺癌中的过氧化物酶体增殖物激活受体γ促进肿瘤进展和转移。
Front Oncol. 2020 Aug 5;10:1371. doi: 10.3389/fonc.2020.01371. eCollection 2020.
5
Negatively Modulates in Tumor Formation of Clear Cell Renal Cell Carcinoma.负向调节在透明细胞肾细胞癌肿瘤形成中的作用。
DNA Cell Biol. 2019 Jul;38(7):700-707. doi: 10.1089/dna.2018.4549. Epub 2019 May 15.
6
PPARG Could Work as a Valid Therapeutic Strategy for the Treatment of Lung Squamous Cell Carcinoma.过氧化物酶体增殖物激活受体γ（PPARG）可作为治疗肺鳞状细胞癌的有效治疗策略。
PPAR Res. 2020 Jun 1;2020:2510951. doi: 10.1155/2020/2510951. eCollection 2020.
7
Role of peroxisome proliferator activated receptor-gamma in bacillus Calmette-Guérin bladder cancer therapy.过氧化物酶体增殖物激活受体-γ 在卡介苗膀胱癌治疗中的作用。
J Urol. 2012 Dec;188(6):2384-90. doi: 10.1016/j.juro.2012.07.109. Epub 2012 Oct 22.
8
The EWSR1/NR4A3 fusion protein of extraskeletal myxoid chondrosarcoma activates the PPARG nuclear receptor gene.骨外黏液样软骨肉瘤的EWSR1/NR4A3融合蛋白激活PPARG核受体基因。
J Pathol. 2009 Jan;217(1):83-93. doi: 10.1002/path.2445.
9
MicroRNA-128 inhibition attenuates myocardial ischemia/reperfusion injury-induced cardiomyocyte apoptosis by the targeted activation of peroxisome proliferator-activated receptor gamma.微小RNA-128抑制通过过氧化物酶体增殖物激活受体γ的靶向激活减轻心肌缺血/再灌注损伤诱导的心肌细胞凋亡。
Mol Med Rep. 2016 Jul;14(1):129-36. doi: 10.3892/mmr.2016.5208. Epub 2016 May 4.
10
TR4 nuclear receptor enhances prostate cancer initiation via altering the stem cell population and EMT signals in the PPARG-deleted prostate cells.TR4核受体通过改变PPARG缺失的前列腺细胞中的干细胞群体和上皮-间质转化信号来增强前列腺癌的起始。
Oncoscience. 2015 Feb 9;2(2):142-50. doi: 10.18632/oncoscience.121. eCollection 2015.
引用本文的文献
1
HK-2 cell response to TGF-β highly depends on cell culture medium formulations.HK-2 细胞对 TGF-β的反应高度依赖于细胞培养基配方。
Histochem Cell Biol. 2024 Jan;161(1):69-79. doi: 10.1007/s00418-023-02237-x. Epub 2023 Sep 26.
2
Integrated Analysis of the Expression Characteristics, Prognostic Value, and Immune Characteristics of PPARG in Breast Cancer.乳腺癌中PPARG的表达特征、预后价值及免疫特征的综合分析
Front Genet. 2021 Sep 9;12:737656. doi: 10.3389/fgene.2021.737656. eCollection 2021.
3
A-FABP-PTEN/AKT Regulates Insulin Resistance in Preadipocyte Cell 3T3-L1 Cells.A-FABP-PTEN/AKT调节前脂肪细胞3T3-L1细胞中的胰岛素抵抗。
Diabetes Metab Syndr Obes. 2021 May 11;14:2103-2110. doi: 10.2147/DMSO.S305872. eCollection 2021.
本文引用的文献
1
Identification of Ppar-modulated miRNA hubs that target the fibrotic tumor microenvironment.鉴定受 Ppar 调控的 miRNA 枢纽，靶向纤维化肿瘤微环境。
Proc Natl Acad Sci U S A. 2020 Jan 7;117(1):454-463. doi: 10.1073/pnas.1909145117. Epub 2019 Dec 23.
2
Influence of Liver Fibrosis on Lobular Zonation.肝纤维化对肝小叶分区的影响。
Cells. 2019 Dec 2;8(12):1556. doi: 10.3390/cells8121556.
3
The pyrrolizidine alkaloid senecionine induces CYP-dependent destruction of sinusoidal endothelial cells and cholestasis in mice.吡咯里西啶生物碱千里光碱诱导小鼠肝窦内皮细胞细胞色素依赖破坏和胆汁淤积。
Arch Toxicol. 2020 Jan;94(1):219-229. doi: 10.1007/s00204-019-02582-8. Epub 2019 Oct 12.
4
Prediction of human drug-induced liver injury (DILI) in relation to oral doses and blood concentrations.预测与口服剂量和血液浓度相关的人体药物性肝损伤（DILI）。
Arch Toxicol. 2019 Jun;93(6):1609-1637. doi: 10.1007/s00204-019-02492-9. Epub 2019 Jun 27.
5
Liver fibrosis: Which mechanisms matter?肝纤维化：哪些机制至关重要？
Clin Liver Dis (Hoboken). 2016 Oct 27;8(4):94-99. doi: 10.1002/cld.581. eCollection 2016 Oct.
6
Toxicogenomics directory of rat hepatotoxicants in vivo and in cultivated hepatocytes.大鼠在体和原代肝细胞肝毒物毒理学基因组目录。
Arch Toxicol. 2018 Dec;92(12):3517-3533. doi: 10.1007/s00204-018-2352-3. Epub 2018 Dec 3.
7
Genetic determinants of steatosis and fibrosis progression in paediatric non-alcoholic fatty liver disease.儿童非酒精性脂肪性肝病中脂肪变性和纤维化进展的遗传决定因素。
Liver Int. 2019 Mar;39(3):540-556. doi: 10.1111/liv.14006. Epub 2018 Dec 21.
8
Bile Microinfarcts in Cholestasis Are Initiated by Rupture of the Apical Hepatocyte Membrane and Cause Shunting of Bile to Sinusoidal Blood.胆汁微梗死在胆汁淤积中是由肝细胞顶膜破裂引发的，并导致胆汁分流到窦状隙血液。
Hepatology. 2019 Feb;69(2):666-683. doi: 10.1002/hep.30213. Epub 2018 Nov 19.
9
Spatio-temporal visualization of the distribution of acetaminophen as well as its metabolites and adducts in mouse livers by MALDI MSI.利用 MALDI MSI 对乙酰氨基酚及其代谢物和加合物在小鼠肝脏中的分布进行时空可视化。
Arch Toxicol. 2018 Sep;92(9):2963-2977. doi: 10.1007/s00204-018-2271-3. Epub 2018 Jul 23.
10
Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies.欧洲肝病负担：流行病学和危险因素分析，以确定预防政策。
J Hepatol. 2018 Sep;69(3):718-735. doi: 10.1016/j.jhep.2018.05.011. Epub 2018 May 17.
Zotero 插件